[강소제약사 리뷰]② 내수 의존도 98% 유유제약, 해외로 눈 돌린다

Yuyu Pharma's strategic pivot from a generic-drug dominated domestic market (98% dependency) to R&D-driven biotech signals a critical challenge facing traditional Korean pharmaceutical companies. By establishing a U.S. subsidiary in 2025 and pursuing veterinary pharmaceutical innovation, the company exemplifies how legacy generic manufacturers must embrace innovation to break growth stagnation. This transformation reflects broader industry pressures for Korean pharma to shift from commodity products to differentiated, globally competitive offerings.